TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio (NASDAQ: TELA) announced that its Compensation Committee has approved inducement grants of restricted stock units covering 5,400 shares to six newly-hired employees. The grants, dated November 1, 2024, were made under Nasdaq Rule 5635(c)(4) as part of employment compensation packages. These restricted stock units will vest equally over four years, contingent on continued employment with the company.
TELA Bio (NASDAQ: TELA) ha annunciato che il suo Comitato per la Compensazione ha approvato assegnazioni di incentivo di unità azionarie negoziabili per un totale di 5.400 azioni a sei nuovi assunti. Le assegnazioni, datate 1 novembre 2024, sono state effettuate secondo la Regola 5635(c)(4) del Nasdaq come parte dei pacchetti di compensazione per i dipendenti. Queste unità azionarie restrittive matureranno in modo uniforme su un periodo di quattro anni, a condizione che i dipendenti rimangano in servizio con l'azienda.
TELA Bio (NASDAQ: TELA) anunció que su Comité de Compensación ha aprobado asignaciones de incentivos de unidades de acciones restringidas que cubren 5,400 acciones para seis empleados recién contratados. Las asignaciones, con fecha del 1 de noviembre de 2024, se realizaron bajo la Regla 5635(c)(4) de Nasdaq como parte de los paquetes de compensación por empleo. Estas unidades de acciones restringidas se consolidarán de manera uniforme durante cuatro años, sujeto a la continuación del empleo en la empresa.
TELA Bio (NASDAQ: TELA)는 보상위원회가 새로 채용된 6명의 직원에게 5,400주에 해당하는 제한 주식 단위의 유인 보상을 승인했다고 발표했습니다. 2024년 11월 1일자로 기재된 이 보상은 고용 보상 패키지의 일환으로 Nasdaq 규칙 5635(c)(4)에 따라 이루어졌습니다. 이 제한 주식 단위는 4년 동안 균등하게 확정됩니다, 회사와의 지속적인 고용을 조건으로 합니다.
TELA Bio (NASDAQ: TELA) a annoncé que son Comité de Rémunération a approuvé des attributions incitatives d'unités d'actions restreintes couvrant 5 400 actions pour six nouveaux employés. Les attributions, datées du 1er novembre 2024, ont été faites conformément à la règle 5635(c)(4) du Nasdaq dans le cadre des packages de rémunération des employés. Ces unités d'actions restreintes s'acquerront progressivement sur une période de quatre ans, sous réserve du maintien de l'emploi au sein de l'entreprise.
TELA Bio (NASDAQ: TELA) gab bekannt, dass der Vergütungsausschuss Anreizvergaben von beschränkten Aktieneinheiten für insgesamt 5.400 Aktien an sechs neu eingestellte Mitarbeiter genehmigt hat. Die Vergaben, datiert auf den 1. November 2024, wurden gemäß der Nasdaq-Regel 5635(c)(4) als Teil der Vergütungspakete für Mitarbeiter vorgenommen. Diese beschränkten Aktieneinheiten werden über einen Zeitraum von vier Jahren gleichmäßig anfallen, vorausgesetzt, dass das Beschäftigungsverhältnis mit dem Unternehmen fortgesetzt wird.
- Stock-based compensation structure helps align employee interests with shareholders
- Expansion of workforce with six new hires indicates company growth
- Potential shareholder dilution from issuance of 5,400 new shares
MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 5,400 shares of its common stock to six newly-hired employees, with a grant date of November 1, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
The restricted stock units will vest in equal annual installments over four years, subject to each individual's continued service with TELA Bio through the applicable vesting dates.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Greg Chodaczek
332-895-3230
ir@telabio.com
FAQ
How many shares were granted in TELA Bio's November 2024 inducement grants?
What is the vesting schedule for TELA Bio's November 2024 inducement grants?
How many employees received TELA Bio's November 2024 inducement grants?
Under which Nasdaq rule were TELA Bio's November 2024 inducement grants issued?
